Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Jan 9:12:1037964.
doi: 10.3389/fonc.2022.1037964. eCollection 2022.

Successful treatment of a patient with advanced lung adenocarcinoma (EGFR-T790M and C797S cis) with lazertinib: A case report and literature review

Yue Fang  1 , Qiankun Zhang  1 , Weimin Wang  1 , Juanjuan Tong  1 , Xialin Li  1
Affiliations
Case Reports

Successful treatment of a patient with advanced lung adenocarcinoma (EGFR-T790M and C797S cis) with lazertinib: A case report and literature review

Yue Fang et al. Front Oncol. .

Abstract

Lazertinib has been shown to treat non-small cell lung cancer (NSCLC) patients with EGFR-T790M, Ex19del, and L858R mutations. However, there are still no studies to prove that lazertinib could be used in patients with EGFR-T790M and C797s cis mutations in NSCLC. We report a case of a patient with advanced lung adenocarcinoma with EGFR-T790M and C797s cis mutations who were treated with lazertinib and achieved satisfactory efficacy without serious side effects. And the scratch assay and colony-forming unit assay were performed using lung adenocarcinoma cells from patients, the results showed that both lazertinib and amivantamab could inhibit the proliferation and migration of lung adenocarcinoma cells to some extent, and the inhibitory effect of lazertinib was better than that of amivantamab (p < 0. 01), while the inhibitory effect of lazertinib combined with amivantamab was not statistically different from that of lazertinib alone(p>0.05). This finding suggests that lazertinib may be an effective treatment option for patients with lung adenocarcinoma presenting with EGFR-T790M and C797s cis mutations.

Keywords: C797s; EGFR-T790M; case report; lazertinib; lung adenocarcinoma.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted without any commercial or financial relationships and withoutpotential conflicts of interest.

Figures

Figure 1
Figure 1
Biopsy pathology of a tumor of the lung lesion. (A) HE staining of the patient’s lung lesion, (B) IHC staining of the patient’s lung lesion.
Figure 2
Figure 2
The cranial MR and CT of the chest before and after lazertinib and amivantamab treatment. (A) In May 2021, cranial MR showed multiple abnormal signals in the left frontoparietal-occipital lobe, basal ganglia region, thalamus, and right cerebellar hemisphere; (B) In July 2021, CT of the chest showed pulmonary atelectasis and pleural effusion.
Figure 3
Figure 3
The CT of the chest after lazertinib and amivantamab treatment. (A) Increased size and number of diffuse nodules in both lungs on chest CT after amivantamab alone on October 9, 2021; (B) Decreased size and number of diffuse nodules in both lungs on chest CT after lazertinib in combination with amivantamab on December 30, 2021.
Figure 4
Figure 4
Timeline of treatment.
Figure 5
Figure 5
Figure of analysis process.
Figure 6
Figure 6
The effect of lazertinib and amivantamab on migration and proliferation of patient’s lung adenocarcinoma cells. (A) Scratch assay shows lazertinib inhibits migration ability of lung adenocarcinoma cells better than amivantamab; (B) Colony-forming unit assays shows lazertinib inhibits lung adenocarcinoma cell proliferation ability more than amivantamab. *p < 01, ***p < 0.001.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. . Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin (2021) 71:209–49. doi: 10.3322/caac.21660 - DOI - PubMed
    1. Nooreldeen R, Bach H. Current and future development in lung cancer diagnosis. Int J Mol Sci (2021) 22(16):8661. doi: 10.3390/ijms22168661 - DOI - PMC - PubMed
    1. Spella M, Stathopoulos GT. Immune resistance in lung adenocarcinoma. Cancers (Basel) (2021) 13(3):384. doi: 10.3390/cancers13030384 - DOI - PMC - PubMed
    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin (2017) 67(1):7–30. doi: 10.3322/caac.21387 - DOI - PubMed
    1. Tan DS, Yom SS, Tsao MS, Pass HI, Kelly K, Peled N, et al. . The international association for the study of lung cancer consensus statement on optimizing management of EGFR mutation-positive non-small cell lung cancer: Status in 2016. J Thorac Oncol (2016) 11(7):946–63. doi: 10.1016/j.jtho.2016.05.008 - DOI - PubMed

Publication types